Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

Prior treatment

• Presence of surgical contraindications, a history of prior brain surgery such as deep brain stimulation (DBS), pallidotomy, or extrapyramidal surgery, or any other neurosurgical procedure that the investigator deems would interfere with participation in this trial.
• Previous cranial imaging showing structural brain abnormalities, cerebrovascular malformations, intracranial tumors, risk of intracranial hemorrhage, traumatic brain injury, or other significant anomalies.
• Current or prior history of a malignant tumor.
• Current participation in another clinical trial, or participation in any other clinical trial within 3 months prior to the screening period.
• Prior history of gene therapy before screening.
• Receipt of stem cell therapy within 6 months prior to the screening period.
• Use of other investigational drugs within 4 weeks prior to screening or within 5 half-lives of the drug (whichever is longer), or any medication judged by the investigator to interfere with the trial.
• Receipt of a live vaccine within 2 months prior to the screening period, or any vaccination within 30 days prior to the screening period.

Other illness

• Diagnosis of atypical or secondary parkinsonian syndromes (e.g., Parkinson-plus syndromes, hereditary parkinsonian syndromes, drug-induced parkinsonism).
• Positive screening for infectious diseases: positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B virus DNA (HBV-DNA), positive for Hepatitis C virus RNA (HCV-RNA), positive for Human Immunodeficiency Virus (HIV), or seropositive for syphilis.
• Currently undergoing antiviral treatment for Hepatitis B or C.
• History of a severe allergic reaction, allergy to contrast agents, or inability to tolerate surgical anesthesia.
• History of alcohol dependence or drug addiction, with an inability to adhere to medical advice to abstain from alcohol during the trial period.

Lab values

• Abnormal liver or kidney function, defined as: Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>1.5 times the upper limit of normal (ULN), or serum creatinine (Cr) \>1.5 times the ULN.
• Presence of unstable or severe concomitant systemic diseases, including but not limited to active tuberculosis, or diseases of the cardiovascular, respiratory, digestive, urinary, neuropsychiatric (e.g., epilepsy), hematologic, or immune systems, or abnormal laboratory values that, in the judgment of the investigator, would make the subject unsuitable for the trial.

Other

• A Mini-Mental State Examination (MMSE) score of \<24.
• A Patient Health Questionnaire-9 (PHQ-9) score of ≥16.
• Coagulation dysfunction or current use of anticoagulant agents.
• Female subjectsparticipants who are pregnant or lactating.
• Any subject deemed unsuitable for enrollment based on the investigator's assessment.

• Clinically confirmed diagnosis of idiopathic Parkinson's Disease (PD) in accordance with the 2015 Movement Disorder Society (MDS) diagnostic criteria.
• Participants aged between 40 and 65 years, inclusive, of any gender.
• A disease history of five years or more.
• A Hoehn and Yahr (H-Y) stage of 2.5 to 4 in the Of-state.
• An adeno-associated virus (AAV) neutralizing antibody titer of fit thecriteria.
• A Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score greater than 35 in the Off-state, with an improvement of at least 30% following an acute levodopa challenge test.
• Stable anti-Parkinsonian medication regimen prior to the screening period for at least four weeks.
• The subject must agree to postpone any other neurosurgical procedures (including deep brain stimulation) during the main study phase, with the exception of emergency neurosurgery for life-threatening conditions.
• The subject must agree not to participate in other therapeutic interventional studies during the main study phase.
• The subject must agree not to undergo vaccination during the main study phase.
• Commitment to using a reliable method of contraception from the screening period until at least 52 weeks post-infusion.
• The subject must be compliant and capable of attending regular follow-up appointments. The subject must be able to accurately complete a PD patient diary during the follow-up period, with assistance from family members, guardians, or caregivers permitted.
• The subject must be fully informed about the nature, objectives, procedures, and potential adverse effects of the clinical trial, and must voluntarily consent to participate by signing the informed consent form. In cases where the subject is unable to read, a legally authorized representative or an impartial witness may read the informed consent form and other written materials to them and witness the consent process.